Efficacy and safety of chemotherapy for newly diagnosed advanced XXXX with @entity1211 .

@entity1 @entity137 @entity390 @entity417 @entity1149 @entity2 @entity1398 @entity1211
BACKGROUND: @entity1211 ( @entity1211 ) is a serious complication in @entity1 with @entity2 . The benefit of chemotherapy for @entity2 @entity1 with @entity1211 remains unknown. This study was conducted to elucidate the efficacy and safety of chemotherapy for advanced @entity1149 ( @entity1149 ) in @entity1 with @entity1211 . METHODS: Newly diagnosed @entity1 with advanced (i.e. stage IIIB and IV) @entity1149 with @entity1211 who received systemic chemotherapy were studied. Response rates, progression-free survival (PFS), overall survival (OS), and @entity137 were retrospectively analyzed. RESULTS: In this study, 21 @entity1 who received chemotherapy plus anticoagulation therapy between December 2009 and February 2011 were included. The objective response and disease control rates within the first regimen were 14.29% (3/21) and 76.19 %(16/21), respectively. The median PFS, one-year survival rate, and median OS were 5.50 months, 33.30%, and 8.70 months, respectively. The main grade 3/4 @entity137 observed included @entity1398 (28.57%), @entity390 4 (19.05%), and @entity417 2 (9.52%). Major bleeding was not observed. CONCLUSION: Chemotherapy for newly diagnosed @entity1 with advanced @entity1149 and @entity1211 was feasible and had acceptable @entity137 ; however, the survival of these @entity1 remained inferior to that of @entity1 without @entity1211 .
